Dr Andrew Jackson - Research Biochemist

      Dr Andrew Jackson -  Research Biochemist
      Leicester-Loughborough Diet, Lifestyle and  Physical Activity BRU, School of Sport, Exercise and Health Sciences, Sir John Beckwith Centre for Sport. Loughborough University


      Andy jackson
      Research interests

      • Enzymology of muscle contraction.
      • Biologically active molecules secreted by fungi
      • Mechanism of action of the quinolone and coumarin classes of antibiotics.
      • Molecular Biology Group expressing and purifying proteins for the various drug discovery programs.
      • Proteomics and biomarker discovery
      • Development of novel biosensor platforms
      • He has experience in molecular biology, all aspects of protein biochemistry, proteomics and biomarker identification.


      Current projects


      • Analysis of biological samples for several exercise and health based studies
      • Development of aptamer based cytokine detection
      • Responsible for the analytical biochemistry and molecular biology aspects of the BRU studies.

       

      Current teaching activities

       

      • Laboratory supervision of the Loughborough based PhD students.
      • Introduction to practical analytical biochemistry (theory and practical workshops)

       

      Contact

      Dr Andrew Jackson - Biomedical Research Unit (BRU)
      Leicester-Loughborough Diet, Lifestyle & Physical Activity BRU
      School of Sport, Exercise and Health Sciences
      Sir John Beckwith Centre for Sport
      Loughborough University
      Leicestershire, UK. LE11 3TU

      Tel: +44 (0) 1509 226324

      http://www.ll.dlpa.bru.nihr.ac.uk/

       

      PEER REVIEWED PUBLICATIONS

       

      1. Faulkner SH, Spilsbury KL, Harvey J, Jackson AP, Huang, J, Tok, A, Nimmo MA. The detection and measurement of interleukin-6 in venous and capillary blood samples and sweat collected at rest and during exercise. European Journal of Applied Physiology 10.1007/s00421-014-2851-8 2014
      2. JR Morling, JA Fallowfield, RM Williamson, LD Lee, AP Jackson, S Glancy, RM Reynolds, PC Hayes, IN Guha, MWJ Strachan, JF Price. Non-invasive hepatic biomarkers (ELF and CK18) in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study.
      3. Liver International, 34 (8), 1267-1277, 2014
      4. Faulkner SH, Spilsbury KL, Harvey J, Jackson AP, Huang J, Platt M, Tok A, Nimmo, MAThe detection and measurement of interleukin-6 in venous and capillary blood samples, and in sweat collected at rest and during exercise. European Journal of Applied Physiology, 114 (6), 1207-16, 2014
      5. Aithal G. P, Guha N, Fallowfield J.A, CastéraL, Jackson A.P, Biomarkers in liver disease: emerging methods and potential applications
      6. Liu Y. Z, Jackson A. P, Cosgrove S. D. Contribution of calcium-containing crystals to cartilage degradation and synovial inflammation in osteoarthritis. Osteoarthritis and cartilage , 17(10), 1333-1340, 2009
      7. Murray CM. Hutchinson R. Bantick JR. Belfield GP. Benjamin AD. Brazma D. Bundick RV. Cook ID. Craggs RI. Edwards S. Evans LR. Harrison R. Holness E. Jackson AP. Jackson CG. Kingston LP. Perry MW. Ross AR. Rugman PA. Sidhu SS. Sullivan M. Taylor-Fishwick DA. Walker PC. Whitehead YM. Wilkinson DJ. Wright A. Donald DK. Monocarboxylate transporter MCT1 is a target for immunosuppression. Nature Chemical Biology. 1(7):371-6, 2005
      8. Lawson C. Walker C. Awford J. Biffen M. Mallinder P. Jackson A. Purification and characterization of recombinant rat mast cell protease 7 expressed in Pichia pastoris. Protein Expression & Purification. 25(2):256-62, 2002
      9. Morais Cabral JH. Jackson AP. Smith CV. Shikotra N. Maxwell A. Liddington RC. Crystal structure of the breakage-reunion domain of DNA gyrase.
      10. Blandamer MJ. Briggs B. Cullis PM. Jackson AP. Maxwell A. Reece RJ.Domain structure of Escherichia coli DNA gyrase as revealed by differential scanning calorimetry.
      11. Jackson AP. Maxwell A. Identifying the catalytic residue of the ATPase reaction of DNA gyrase. Proceedings of the National Academy of Sciences of the United States of America. 90(23):11232-6, 1993
      12. Ali JA. Jackson AP. Howells AJ. Maxwell A.The 43-kilodalton N-terminal fragment of the DNA gyrase B protein hydrolyzes ATP and binds coumarin drugs.
      13. Jackson AP. Maxwell A. Wigley DB. Preli Journal of Molecular Biology. 217(1):15-7, 1991
      14. Cross RA. Jackson AP. Citi S. Kendrick-Jones J. Bagshaw CR. Active site trapping of nucleotide by smooth and non-muscle myosins. Journal of Molecular Biology. 203(1):173-81, 1988
      15. Jackson AP. Bagshaw CR. Kinetic trapping of intermediates of the scallop heavy meromyosin adenosine triphosphatase reaction revealed by formycin nucleotides. Biochemical Journal. 251(2):527-40, 1988
      16. Jackson AP. Bagshaw CR.Transient-kinetic studies of the adenosine triphosphatase activity of scallop heavy meromyosin. Biochemical Journal. 251(2):515-26, 1988
      17. Jackson AP. Timmerman MP. Bagshaw CR. Ashley CC. The kinetics of calcium binding to fura-2 and indo-1. FEBS Letters. 216(1):35-9, 1987
      18. Jackson AP. Warriner KE. Bagshaw CR. Measurement of single turnovers of scallop myosin ATPase in the filamentous state. Biochemical Society Transaction 15, 900-901, 1987
      19. Jackson AP. Warriner KE. Wells C. Bagshaw CR. The actin-activated ATPase of regulated and unregulated scallop heavy meromyosin. FEBS Letters. 197 (1,2), 154-158, 1986

       

       

      Patents

       

      SCREENING METHOD

      ASTRAZENECA AB; ASTRAZENECA UK LTD

      This invention arises from the discovery that compounds capable of blocking cellular monocarboxylate transport can inhibit lymphocyte proliferation, offering up these compounds as therapeutic agents in various immune-mediated disorders and cancers.

      Sullivan, Michael; Murray, Clare, Margaret; Hutchinson, Raymond; Donald, David, Keith; Jackson, Clive, Geoffrey; Jackson, Andrew, Paul; Bantick, John, Raymond; Cook, Ian, David

      Application No. WO2003GB5072A Filed 20031121 Published 20050616

      WO2005054852 A1

       

      TUMOUR NECROSIS FACTOR ANTAGONIST

      XENOVA LTD

      Vinigrol or a pharmaceutically acceptable salt thereof is useful as a tumour necrosis factor antagonist.

      Norris, David Bradley; DePledge, Paul; Jackson, Andrew Paul

      Application No. WO1990GB1801A Filed 19901122 Published 19910613, WO1991007953 A1